Compare STRIDES PHARMA SCIENCE with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs TORRENT PHARMA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE TORRENT PHARMA STRIDES PHARMA SCIENCE/
TORRENT PHARMA
 
P/E (TTM) x 14.8 59.8 24.8% View Chart
P/BV x 0.9 6.3 13.8% View Chart
Dividend Yield % 0.6 0.8 68.5%  

Financials

 STRIDES PHARMA SCIENCE   TORRENT PHARMA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
TORRENT PHARMA
Mar-18
STRIDES PHARMA SCIENCE/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1471,550 74.0%   
Low Rs6421,144 56.1%   
Sales per share (Unadj.) Rs317.2354.7 89.4%  
Earnings per share (Unadj.) Rs7.840.1 19.6%  
Cash flow per share (Unadj.) Rs25.164.2 39.0%  
Dividends per share (Unadj.) Rs2.0014.00 14.3%  
Dividend yield (eoy) %0.21.0 21.5%  
Book value per share (Unadj.) Rs274.3273.1 100.4%  
Shares outstanding (eoy) m89.50169.22 52.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.83.8 74.3%   
Avg P/E ratio x114.033.6 339.3%  
P/CF ratio (eoy) x35.721.0 170.2%  
Price / Book Value ratio x3.34.9 66.2%  
Dividend payout %25.534.9 73.0%   
Avg Mkt Cap Rs m80,058227,897 35.1%   
No. of employees `0002.514.7 17.1%   
Total wages/salary Rs m4,34111,353 38.2%   
Avg. sales/employee Rs Th11,325.84,083.0 277.4%   
Avg. wages/employee Rs Th1,731.4772.3 224.2%   
Avg. net profit/employee Rs Th280.1461.3 60.7%   
INCOME DATA
Net Sales Rs m28,39460,021 47.3%  
Other income Rs m9412,988 31.5%   
Total revenues Rs m29,33463,009 46.6%   
Gross profit Rs m3,96513,493 29.4%  
Depreciation Rs m1,5404,086 37.7%   
Interest Rs m1,9623,085 63.6%   
Profit before tax Rs m1,4039,310 15.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m972,529 3.8%   
Profit after tax Rs m7026,781 10.4%  
Gross profit margin %14.022.5 62.1%  
Effective tax rate %6.927.2 25.5%   
Net profit margin %2.511.3 21.9%  
BALANCE SHEET DATA
Current assets Rs m24,83652,623 47.2%   
Current liabilities Rs m18,99352,022 36.5%   
Net working cap to sales %20.61.0 2,053.4%  
Current ratio x1.31.0 129.3%  
Inventory Days Days71120 59.3%  
Debtors Days Days11376 148.8%  
Net fixed assets Rs m34,28985,016 40.3%   
Share capital Rs m895846 105.8%   
"Free" reserves Rs m23,65145,376 52.1%   
Net worth Rs m24,54646,222 53.1%   
Long term debt Rs m15,51341,115 37.7%   
Total assets Rs m65,437142,432 45.9%  
Interest coverage x1.74.0 42.7%   
Debt to equity ratio x0.60.9 71.1%  
Sales to assets ratio x0.40.4 103.0%   
Return on assets %4.16.9 58.8%  
Return on equity %2.914.7 19.5%  
Return on capital %6.914.2 48.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69714,580 107.7%   
Fx outflow Rs m7353,600 20.4%   
Net fx Rs m14,96210,980 136.3%   
CASH FLOW
From Operations Rs m1,8718,942 20.9%  
From Investments Rs m5,826-47,070 -12.4%  
From Financial Activity Rs m-10,15734,174 -29.7%  
Net Cashflow Rs m-2,615-3,655 71.5%  

Share Holding

Indian Promoters % 27.7 71.5 38.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 7.0 538.5%  
FIIs % 8.6 12.6 68.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 8.8 294.3%  
Shareholders   56,241 26,511 212.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   DIVIS LABORATORIES  WOCKHARDT  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 32.5% (Quarterly Result Update)

Jul 25, 2019 | Updated on Jul 25, 2019

For the quarter ended June 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 32.5% YoY). Sales on the other hand came in at Rs 20 bn (up 8.0% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

TORRENT PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 166.7% (Quarterly Result Update)

May 22, 2019 | Updated on May 22, 2019

For the quarter ended March 2019, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 166.7% YoY). Sales on the other hand came in at Rs 19 bn (up 7.8% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

TORRENT PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 324.1% (Quarterly Result Update)

Jan 31, 2019 | Updated on Jan 31, 2019

For the quarter ended December 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 324.1% YoY). Sales on the other hand came in at Rs 21 bn (up 38.9% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Sep 20, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS